Clinical Trial Update
CRISM Therapeutics Corporation has announced the successful completion of the Site Initiation Visit at its lead NHS clinical trial site, paving the way for patient recruitment in the coming weeks for its Phase II study. This study will evaluate irinotecan ChemoSeed®, the company's proprietary implantable drug delivery technology designed for sustained, localised delivery of irinotecan directly into the tumour margin following glioblastoma resection.
Select text to share a quote on X · sign in to keep highlights & notes in your CRTX notes
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.
CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")
Clinical Trial Update
Site Initiation Visit Complete
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, confirms that the Site Initiation Visit at the lead NHS clinical trial site has now completed successfully.
The Company is working closely with the clinical site, NHS Trust and its clinical partners to enable patient recruitment to commence in the coming weeks.
The Phase II study will evaluate irinotecan ChemoSeed®, the Company's proprietary implantable drug delivery technology designed to provide sustained, localised delivery of irinotecan directly into the tumour margin following surgical resection of a glioblastoma tumour.
The Company's LEI is 213800XFW6MKVCHHPW88.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.